We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Strategic Partners A/s | LSE:0CUM | London | Ordinary Share | DK0062502894 | STRATEGIC PARTNERS ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 61,590.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 0 | -26.05M | -0.7377 | -122.00 | 2.17T |
Company announcement Orphazyme A/SNo. 34/2022 www.orphazyme.comCompany Registration No. 32266355
Copenhagen, Denmark, September 19, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”) announces an update to the Company’s financial calendar in regard to the publication of the Company’s Interim Report First Half 2022. The Interim Report First Half 2022 will be published on September 26, 2022, previously September 20, 2022. Additional time is required to conclude the presentation of the financial statements following the sale of substantially all Orphazyme’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm, Inc. (KMPH: NASDAQ, NY) which completed during the reporting period.
Interim Report First Half 2022September 26, 2022
For additional information, please contact
Orphazyme A/S
Anders Vadsholt, Chief Executive Officer and Chief Financial Officer +45 28 98 90 55
Attachment
1 Year Strategic Partners A/s Chart |
1 Month Strategic Partners A/s Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions